<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951899</url>
  </required_header>
  <id_info>
    <org_study_id>08-008284</org_study_id>
    <secondary_id>R01DK078646</secondary_id>
    <secondary_id>R01DK082396</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT00951899</nct_id>
  </id_info>
  <brief_title>The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics</brief_title>
  <official_title>The Effect of Colesevelam Hydrochloride on Disposition Index and Incretin Concentrations in Subjects With Type 2 Diabetes Using a Double-blind, Placebo-controlled, Parallel-group Study Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study was to determine the metabolic mechanism for a certain type
      medication's ability to lower blood sugar after a meal in Type 2 Diabetics, in order to
      develop a better understanding of it's potential role in the treatment of obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Welchol (colesevelam hydrochloride) is a bile acid sequestrant (BAS) recently approved by the
      FDA for glucose lowering in patients with type 2 diabetes mellitus. Four randomized,
      controlled clinical studies in subjects with type 2 diabetes have demonstrated significant
      treatment difference in HbA1c (-0.5%). Study durations ranged from 12-26 weeks of therapy. In
      diabetes clinical studies, a therapeutic response to colesevelam hydrochloride, as reflected
      by reduction in A1c was initially noted following 4-6 weeks of treatment and reached maximal
      or near-maximal effect after 12-18 weeks of treatment. Reductions in both fasting plasma
      glucose and postprandial concentrations have been demonstrated. Simple measures of insulin
      secretion and action have suggested that this is due to improved insulin action rather than
      improved insulin secretion. The mechanism by which bile acids interact with the key pathways
      regulating glucose concentrations is largely unknown. The investigators propose a randomized,
      double-blind, placebo controlled trial with a parallel-group design where subjects are
      randomized to receive colesevelam or matching placebo for a 12 week treatment period. A
      labeled mixed meal before and after treatment will be used to measure intestinal transit,
      postprandial and fasting glucose fluxes, insulin secretion and action as well as
      enteroendocrine secretion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Disposition Index</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Total Disposition Index (DI) is a calculated value which represents the ability of a person's pancreas to lower blood glucose. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Fasting Glucagon-Like Peptide-1 (GLP-1) Concentration</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>GLP-1 is thought to increase insulin secretion and was measured in the blood and reported in picomoles per liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Concentration</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
    <description>Fasting glucose concentrations were measured at baseline and 2 hours post-meal using the glucose oxidase method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>HbA1c is the percent of red blood cell hemoglobin with glucose attached to it and an indicator of average blood glucose over the previous two to three months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Concentration</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
    <description>Fasting insulin levels were measured in the plasma using a chemiluminescence assay and is reported in nanomoles over 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Endogenous Glucose Production (EGP)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
    <description>EGP was measured using a triple-tracer mixed meal and calculated using the Steele's model, reported in micromoles per kilogram per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Meal Glucose Appearance (Meal Ra)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
    <description>Meal Ra was measured using a triple-tracer mixed meal and reported in micromols in 6 hours. Meal derived glucose is a function of both gastric emptying and splanchnic meal extraction. Meal Ra was calculated by multiplying rate of appearance of [1-^13C] glucose (obtained from the infusion rate of [6-^3H] glucose and the clamped plasma ratio of [6-^3H] glucose and [1-^13C] glucose) by the meal enrichment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Meal Glucose Disappearance (Meal Rd)</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
    <description>Meal Rd is the rate at which glucose leaves the systemic circulation. It was measured using a triple-tracer mixed meal and reported in micromols over 6 hours. Meal Rd was calculated by subtracting the change in glucose mass from the overall rate of glucose appearance (i.e., meal Ra + EGP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Values</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Lipids are fat-like substances in the blood.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with colesevelam hydrochloride in addition to Metformin and Diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo in addition to Metformin and Diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.</description>
    <arm_group_label>Colesevelam</arm_group_label>
    <other_name>Welchol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>Subjects were instructed to follow a weight maintenance diet (~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.</description>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.</description>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage XR</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Fortamet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 35-70 years old.

          -  Body Mass Index greater than 19kg/m^2 or less than 40kg/m^2 or a total weight less
             than 130 kilograms.

          -  Negative pregnancy test for women of childbearing potential.

          -  Absence of gastrointestinal symptoms.

          -  Signed informed consent.

          -  Treatment with diet and/or metformin. Subjects must be on stable therapeutic doses of
             metformin and/or lipid-lowering agents for more than 3 months.

        Exclusion Criteria:

          -  Structural or metabolic diseases/conditions that affect the gastrointestinal system,
             or functional gastrointestinal disorders. A screening Bowel Disease Questionnaire will
             be used to exclude subjects with irritable bowel syndrome. Patients with a history of
             dysphagia or intestinal motility disorders will be excluded.

          -  Prior history of pancreatitis.

          -  Prior history of hypertriglyceridemia (500mg/dL or greater).

          -  Currently using a bile-acid binding resin such as colesevelam, colestipol, colestimide
             or cholestyramine.

          -  To ensure homogeneity between treatment groups we will exclude subjects with
             insulin-treated type 2 diabetes mellitus, subjects who have received an inhibitors of
             dipeptidyl peptidase 4 (DPP-4 inhibitors) or &quot;gliptins&quot; (a class of oral
             hypoglycemics), Byetta or sulfonylurea agent in the past three months.

          -  HbA1c greater than 9.0%.

          -  Patients who have not been stable on all medications for a period exceeding 3 months.

          -  Use of drugs or agents within the past 2 weeks or planned use in the subsequent 4
             weeks during the study period that:

               -  Alter GI transit including laxatives, magnesium or aluminum-containing antacids,
                  prokinetics, erythromycin, narcotics, anticholinergics, tricyclic
                  antidepressants, Selective Serotonin Reuptake Inhibitors (SSRIs) and newer
                  antidepressants.

               -  Opiate-based analgesic drugs (Note: intermittent or chronic use of aspirin or
                  non-steroidal anti-inflammatory drugs (NSAID) will be allowed).

               -  Antihistamines

               -  Anticholinergic agents

          -  Female subjects who are pregnant or breast-feeding. Females must be either surgically
             sterilized, postmenopausal (&gt;12 months since last menses), or, if of childbearing
             potential, using reliable methods of contraception as determined by the physician.

          -  Clinical evidence (including physical exam and Electrocardiogram) of significant
             cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological,
             neurological, psychiatric, or other disease that interfere with the objectives of the
             study. Any candidate participants with such disorders mentioned will be referred to
             their general physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law JH, Cobelli C, Zinsmeister AR, Rizza RA, Vella A. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes. 2013 Apr;62(4):1094-101. doi: 10.2337/db12-0923. Epub 2012 Dec 18.</citation>
    <PMID>23250357</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <results_first_submitted>April 26, 2013</results_first_submitted>
  <results_first_submitted_qc>June 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2013</results_first_posted>
  <last_update_submitted>October 17, 2013</last_update_submitted>
  <last_update_submitted_qc>October 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>MD, Professor of Medicine, Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Incretins</keyword>
  <keyword>colesevelam</keyword>
  <keyword>hepatobiliary circulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Incretins</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with type 2 diabetes on monotherapy with Metformin were recruited by advertisement from 2009 to 2010 at Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <pre_assignment_details>39 subjects provided written informed consent to participate. One subject lost intravenous access during the baseline study and withdrew consent. The remaining 38 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Colesevelam</title>
          <description>Treatment with colesevelam in addition to metformin and diet</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo plus diet and metformin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are reported for only the randomized subjects (19/19).</population>
      <group_list>
        <group group_id="B1">
          <title>Colesevelam</title>
          <description>Treatment with colesevelam in addition to metformin and diet</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo plus diet and metformin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age is reported for the randomized subjects only.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="5.9"/>
                    <measurement group_id="B2" value="60.2" spread="6.3"/>
                    <measurement group_id="B3" value="61" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender reported for only the randomized subjects.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="4.3"/>
                    <measurement group_id="B2" value="30.4" spread="4.0"/>
                    <measurement group_id="B3" value="30.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Disposition Index</title>
        <description>Total Disposition Index (DI) is a calculated value which represents the ability of a person's pancreas to lower blood glucose. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Intent to treat analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Total Disposition Index</title>
          <description>Total Disposition Index (DI) is a calculated value which represents the ability of a person's pancreas to lower blood glucose. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose.</description>
          <population>Intent to treat analysis population.</population>
          <units>DItot (10^-14 dl/kg/min^2 per pmol/l)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disposition Index at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332" spread="41"/>
                    <measurement group_id="O2" value="253" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disposition Index at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519" spread="169"/>
                    <measurement group_id="O2" value="310" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fasting Glucagon-Like Peptide-1 (GLP-1) Concentration</title>
        <description>GLP-1 is thought to increase insulin secretion and was measured in the blood and reported in picomoles per liter.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fasting Glucagon-Like Peptide-1 (GLP-1) Concentration</title>
          <description>GLP-1 is thought to increase insulin secretion and was measured in the blood and reported in picomoles per liter.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total GLP-1 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="1.8"/>
                    <measurement group_id="O2" value="18.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total GLP-1 at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="2.1"/>
                    <measurement group_id="O2" value="19.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison of mean total GLP-1 concentration from baseline to 12 weeks in Colesevelam subjects</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>A P value &lt; 0.05 was considered statistically significant</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of mean total GLP-1 concentration from baseline to 12 weeks in Placebo subjects</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Concentration</title>
        <description>Fasting glucose concentrations were measured at baseline and 2 hours post-meal using the glucose oxidase method.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Concentration</title>
          <description>Fasting glucose concentrations were measured at baseline and 2 hours post-meal using the glucose oxidase method.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="0.2"/>
                    <measurement group_id="O2" value="7.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.2"/>
                    <measurement group_id="O2" value="7.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmeal Glucose Peak at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="0.6"/>
                    <measurement group_id="O2" value="15.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmeal Glucose Peak at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="0.6"/>
                    <measurement group_id="O2" value="15.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Hemoglobin (HbA1c)</title>
        <description>HbA1c is the percent of red blood cell hemoglobin with glucose attached to it and an indicator of average blood glucose over the previous two to three months.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <description>HbA1c is the percent of red blood cell hemoglobin with glucose attached to it and an indicator of average blood glucose over the previous two to three months.</description>
          <units>Percentage of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="0.1"/>
                    <measurement group_id="O2" value="6.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.2"/>
                    <measurement group_id="O2" value="6.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Concentration</title>
        <description>Fasting insulin levels were measured in the plasma using a chemiluminescence assay and is reported in nanomoles over 6 hours.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Concentration</title>
          <description>Fasting insulin levels were measured in the plasma using a chemiluminescence assay and is reported in nanomoles over 6 hours.</description>
          <units>nmols/6 hrs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Insulin at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="6"/>
                    <measurement group_id="O2" value="50" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="5"/>
                    <measurement group_id="O2" value="51" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmeal Insulin at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="7.9"/>
                    <measurement group_id="O2" value="72.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmeal Insulin at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="6.1"/>
                    <measurement group_id="O2" value="81.9" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Endogenous Glucose Production (EGP)</title>
        <description>EGP was measured using a triple-tracer mixed meal and calculated using the Steele's model, reported in micromoles per kilogram per minute.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Endogenous Glucose Production (EGP)</title>
          <description>EGP was measured using a triple-tracer mixed meal and calculated using the Steele's model, reported in micromoles per kilogram per minute.</description>
          <units>micromol/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EGP at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="0.6"/>
                    <measurement group_id="O2" value="17.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="0.6"/>
                    <measurement group_id="O2" value="17.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Meal Glucose Appearance (Meal Ra)</title>
        <description>Meal Ra was measured using a triple-tracer mixed meal and reported in micromols in 6 hours. Meal derived glucose is a function of both gastric emptying and splanchnic meal extraction. Meal Ra was calculated by multiplying rate of appearance of [1-^13C] glucose (obtained from the infusion rate of [6-^3H] glucose and the clamped plasma ratio of [6-^3H] glucose and [1-^13C] glucose) by the meal enrichment.</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Meal Glucose Appearance (Meal Ra)</title>
          <description>Meal Ra was measured using a triple-tracer mixed meal and reported in micromols in 6 hours. Meal derived glucose is a function of both gastric emptying and splanchnic meal extraction. Meal Ra was calculated by multiplying rate of appearance of [1-^13C] glucose (obtained from the infusion rate of [6-^3H] glucose and the clamped plasma ratio of [6-^3H] glucose and [1-^13C] glucose) by the meal enrichment.</description>
          <units>micromol/6h</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meal appearance glucose at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5941" spread="402"/>
                    <measurement group_id="O2" value="5504" spread="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meal appearance glucose at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5413" spread="289"/>
                    <measurement group_id="O2" value="5613" spread="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Meal Glucose Disappearance (Meal Rd)</title>
        <description>Meal Rd is the rate at which glucose leaves the systemic circulation. It was measured using a triple-tracer mixed meal and reported in micromols over 6 hours. Meal Rd was calculated by subtracting the change in glucose mass from the overall rate of glucose appearance (i.e., meal Ra + EGP).</description>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Meal Glucose Disappearance (Meal Rd)</title>
          <description>Meal Rd is the rate at which glucose leaves the systemic circulation. It was measured using a triple-tracer mixed meal and reported in micromols over 6 hours. Meal Rd was calculated by subtracting the change in glucose mass from the overall rate of glucose appearance (i.e., meal Ra + EGP).</description>
          <units>micromol/6h</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meal Rd at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8642" spread="414"/>
                    <measurement group_id="O2" value="8784" spread="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meal Rd at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8155" spread="314"/>
                    <measurement group_id="O2" value="8761" spread="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Values</title>
        <description>Lipids are fat-like substances in the blood.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>Treatment with colesevelam in addition to metformin and diet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus diet and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Values</title>
          <description>Lipids are fat-like substances in the blood.</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="0.19"/>
                    <measurement group_id="O2" value="4.33" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="0.16"/>
                    <measurement group_id="O2" value="4.00" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.15"/>
                    <measurement group_id="O2" value="1.88" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="0.19"/>
                    <measurement group_id="O2" value="1.55" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipoprotein (HDL) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.06"/>
                    <measurement group_id="O2" value="1.27" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipoprotein (HDL) at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.10"/>
                    <measurement group_id="O2" value="1.20" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Density Lipoprotein (LDL) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="0.17"/>
                    <measurement group_id="O2" value="2.31" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Density Lipoprotein (LDL) at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.14"/>
                    <measurement group_id="O2" value="2.09" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Colesevelam</title>
          <description>Treatment with colesevelam in addition to metformin and diet</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo plus diet and metformin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI ulcer and hemorrhage</sub_title>
                <description>Subject experienced gastric (antral) ulcerations of unknown etiology, causing melena with acute GI blood loss.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low hemoglobin</sub_title>
                <description>Low hemoglobin found during visit with primary MD.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adrian Vella</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3289</phone>
      <email>vella.adrian@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

